Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

A very large percentage of all of these patient segments are currently ... of ZORYVE foam to help patients with scalp and ...

Stationary plaque psoriasis, which is usually a chronic illness ... distal interphalangeal [DIP] arthritis), but sometimes also individual large joints (oligoarthritis). About 40% of patients ...

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable ...

Study authors examined the use of artificial intelligence in machine learning models for the assessment of psoriasis severity, as well as identified future research needs.

Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Patients with plaque psoriasis treated with Johnson & Johnson ... Click here for more. In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies ...

In plaque psoriasis, PONVORY has shown significant efficacy in achieving PASI 75, a measurement of improvement of psoriasis score by week 16 in a large 326 patient study that included two doses of ...

Researchers conducted a retrospective study to investigate the effectiveness of brodalumab for treating difficult-to-manage ...

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis Two trials for active psoriatic arthritis (PsA) with one focusing on ...